• Join Today!

Become a member and connect with:

  • An Active Online Community
  • Articles and Advice on SCD
  • Help Understanding Clinical Trials

Bluebird bio acquires Durham, NC, manufacturing site for lentiviral vector production

bluebird bio said today it has acquired a manufacturing facility in Durham, NC, from an undisclosed seller for $11.5 million, with the goal of producing lentiviral vectors for the company’s cell and gene therapies.

Those therapies, bluebird said, include the cerebral adrenoleukodystrophy treatment Lenti-D, as well as LentiGlobin for transfusion-dependent β-thalassemia and severe sickle cell disease and multiple myeloma treatments bb2121 and bb21217.

bluebird said the acquisition was part of a “significant” investment in manufacturing infrastructure that includes expanding in-house expertise, creating an extensive manufacturing network, and increasing manufacturing capacity.